JW Heparin Sodium Injection 1000 IU

Adult administration

Administered as an intravenous injection or added to the blood during extracorporeal circulation. Before administration, a heparin sensitivity test should be conducted and blood coagulation time measured post-administration to determine the maintenance dose. 1. Extracorporeal circulation (1) General heparinization for artificial kidney: Administer 1,000 to 5,000 IU before starting dialysis, followed by continuous or intermittent administration of 500 to 1,500 IU per hour after initiating dialysis. (2) Local heparinization for artificial kidney.

This drug is a very potent medication and must only be used under strict medical supervision. Care must be taken when administering it to patients with a high risk of bleeding disorders, as it can cause bleeding from almost any part of the body. In some patients, fatal bleeding may occur, so caution is required. Additionally, the benzyl alcohol component in this medication can cause serious respiratory problems in premature infants, therefore it should not be used in neonates or premature babies. It should not be administered to patients who have had allergic reactions to this medication or its constituents, to patients with inappropriate coagulation test results, to patients who are bleeding or at high risk for bleeding, to those with severe liver or kidney disease, to patients who have recently had neurological or eye surgery, or those who have received spinal anesthesia or lumbar puncture. This drug regulates blood coagulation, so during treatment, regular blood coagulation tests and platelet counts should be checked, and administration should be discontinued immediately if there is a sudden decrease in platelet count. This medication should not be stopped abruptly, as there is a risk of thrombosis; the dosage should be gradually reduced. Also, when used in conjunction with this drug, especially with aspirin, non-steroidal anti-inflammatory drugs, or anticoagulants, the risk of bleeding may increase, so medical advice should be sought. Women who are pregnant or potentially pregnant should take special care due to the risk of uterine and placental bleeding, and those who are breastfeeding should also exercise caution due to the benzyl alcohol component. In elderly or pediatric patients, the risk of bleeding may also be higher, so it should be administered with caution. In case of overdose, the risk of bleeding increases, so it is important to promptly inform medical personnel; protamine sulfate can be used as an antidote, but this itself may have side effects, so caution is necessary. Avoid intramuscular injections during the administration of this drug, and do not mix it with other medications for injection. This medication must be used with great care, so it is very important to thoroughly follow medical instructions and undergo regular examinations before and after administration.

Serious side effects

Rash, angioedema, dyspnea, shock, gastrointestinal bleeding, intracranial bleeding, thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombosis (HITT), asthma, hemorrhagic necrosis, severe rash with high fever, severe swelling (edema)

Mild side effects

• Itching
• rash
• chills
• fever
• rhinitis
• bronchial asthma
• tearing
• conjunctivitis
• cyanosis
• tachycardia

This medication is sensitive to light and should be stored in opaque containers. It must also be kept sealed to prevent air exposure in order to maintain its efficacy over time.

Appearance

A transparent liquid that is colorless to light yellow, housed in a brown glass vial.

Package unit

5 mL x 10 vials, 20 mL x 10 vials